查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
2022532

急性呼吸窘迫症候群（ARDS）：市场展望、流行病学、竞争格局、市场预测报告（2025-2035年）

Acute Respiratory Distress Syndrome (ARDS) - Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035
出版日期: | 出版商: Thelansis Knowledge Partners | 英文 155 Pages | 商品交期: 2-3个工作天内

价格
简介目录

市场概览

  • 预计义大利 ARDS 市场将从 2025 年的 6,200 万美元增长到 2035 年的 1.22 亿美元，这反映出在重症监护的进步和支持疗法的增加的推动下，市场实现了中等到强劲的增长。
  • 市场成长并非仅与发病率直接相关，而是受到以下因素的影响：
  • 重症监护室高阶干预措施（体外膜氧合、机械通气等）的使用增加
  • 重症加护病房医疗成本不断上涨
  • 目前的市场规模主要来自支持性照护基础设施（人工呼吸器系统、ICU 管理），而非药物治疗。
  • 未来市场扩张取决于针对 ARDS 潜在发炎和血管机制的标靶治疗的开发和引入。

急性呼吸窘迫症候群（ARDS）概述

急性呼吸窘迫症候群（ARDS）是严重的、危及生命的发炎性肺部疾病，其特征是由于肺泡和毛细血管屏障功能破坏而导致的急性非心源性肺水肿。这会导致瀰漫性肺泡损伤（DAD）、气体交换受损和难治性低氧血症。

ARDS通常是直接肺损伤（例如重症肺炎、吸入性肺炎）或间接全身性疾病（例如败血症或严重创伤）的併发症。其病理生理机制是由不受控制的发炎级联反应所驱动，导致血管渗透性增加、液体渗入肺泡、肺顺应性下降。

诊断和严重程度分类是基于柏林定义，该定义根据低氧血症的程度（PaO2/FiO2 比率）以及是否存在无法用心臟衰竭或体液超负荷解释的双侧浸润，将 ARDS 分为轻度、中度和重度。

目前，尚无核准的针对急性呼吸窘迫症候群（ARDS）的标靶治疗，治疗仍以支持性治疗为主。标准治疗包括肺保护性机械呼吸系统护理（低潮气量、优化呼气末正压通气）、保守的液体管理、预防人工呼吸器相关性肺损伤（VILI）。在重症病例中，会采用俯卧通气、神经肌肉阻断和静脉-静脉体外膜氧合（VV-ECMO）等高阶干预措施来改善氧合和提高存活率。

主要亮点

  • 在美国，预计 2025 年 ARDS 新发病例数将增加到 2035 年的 547,300 例，增幅为 586,700 例，这反映出由于人口老化和严重发病率上升而导致的逐渐增长（年复合增长率为 0.7%）。
  • 儘管盛行率很高，但治疗仍然完全是支持性的，没有核准的疾病修正治疗，这代表着一个重大的未满足需求。
  • 人们越来越关注抗发炎疗法、内皮细胞稳定疗法和再生疗法的研究，预计这将塑造未来的治疗模式。

格式化和更新讯息

  • 详细报告（PDF）
  • 市场预测模型（基于微软Excel）
  • 流行病学数据（MS Excel，互动式工具）
  • 高阶主管洞察（PPT简报）
  • 其他功能：定期更新、自订和顾问支援。
  • 根据 Thelansis 的政策，我们确保所有最新更新在发布前都反映在报告内容和市场模型中。

主要问题

  • 我们如何优化 G8 市场（美国、欧盟 5 国、日本、中国）的药物开发与生命週期管理策略？
  • 从发病率、盛行率、人群组成以及接受药物治疗的患者人数来看，患者数量分别是多少？
  • 未来十年市场收入和病患份额的预测是多少？
  • 哪些因素对市场趋势影响最大？
  • 受访专家对目前和新兴的治疗方法有何看法？
  • 哪款在研发线产品最有前景？其上市潜力及未来市场定位如何？
  • 主要未被满足的需求是什么？ KOL 对目标受众有何期望？
  • 为确保药物核准并顺利进入市场，必须满足哪些关键的监管和支付方要求？

目标国家

  • G8
    • 我们
    • EU5
      • 法国
      • 德国
      • 义大利
      • 西班牙
      • 英国
    • 日本
    • 中国

大公司

  • Changchun Tuohua Pharmaceutical Co., Ltd.
  • Breathe Biologics, Inc.
  • Staidson（Beijing）Biopharmaceuticals Co., Ltd.
  • EnliTISA（Shanghai）Pharmaceutical Co., Ltd.
  • HTIC, Inc
  • BioAegis Therapeutics Inc.
  • Direct Biologics, LLC
  • Implicit Bioscience
  • Dompe Farmaceutici SpA
  • Pharmazz, Inc.
  • Aqualung Therapeutics Corp.
  • Arch Biopartners Inc.
  • Vasomune Therapeutics, Inc.
  • ImmunityBio, Inc.
  • AVM Biotechnology Inc

目录

第一章：主要调查结果及分析师说明

  • 主要趋势：市场概况、SWOT分析、商业性利益与风险等。

第二章：疾病背景

  • 疾病定义、分类、病因和病理生理学、药物标靶等。

第三章：流行病学

  • 重点
  • 发病率/盛行率
  • 已确诊并接受药物治疗的患者人数
  • 合併症
  • 其他相关患者群

第四章 市场规模及预测

  • 重点
  • 市场驱动因素与限制因素
  • 按药物类别分類的趋势
  • 各国具体趋势

第五章 竞争情势

  • 目前的治疗方法
  • 重点
  • 诊断和治疗过程/演算法
  • 主要治疗方法概述及KOL洞察
  • 新兴治疗方法
  • 重点
  • 值得关注的后期新治疗方法－概述、市场上市预期及KOL洞察
  • 值得关注的早期管道

第六章：未满足的需求与目标产品分析

  • 主要未满足的需求以及透过新兴治疗方法实现的未来可能性
  • TPP分析与KOL展望

第七章 监理与报销环境

第八章附录

简介目录

Acute Respiratory Distress Syndrome (ARDS) Market Outlook

Thelansis's "Acute Respiratory Distress Syndrome (ARDS) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report - 2025 To 2035" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Acute Respiratory Distress Syndrome treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Acute Respiratory Distress Syndrome (ARDS) Overview

Acute Respiratory Distress Syndrome (ARDS) is a severe, life-threatening inflammatory lung condition characterized by acute, non-cardiogenic pulmonary edema resulting from disruption of the alveolar-capillary barrier. This leads to diffuse alveolar damage (DAD), impaired gas exchange, and refractory hypoxemia.

ARDS typically arises as a complication of direct pulmonary insults (e.g., severe pneumonia, aspiration) or indirect systemic conditions such as Sepsis and major trauma. The pathophysiology is driven by an uncontrolled inflammatory cascade, leading to increased vascular permeability, alveolar flooding, and loss of lung compliance.

Diagnosis and severity classification are based on the Berlin Definition, which stratifies ARDS into mild, moderate, and severe categories according to the degree of hypoxemia (PaO2/FiO2 ratio) and the presence of bilateral infiltrates not explained by cardiac failure or fluid overload.

There are currently no approved targeted pharmacological therapies for ARDS, and management remains entirely supportive. Standard of care relies on lung-protective mechanical ventilation strategies (low tidal volume, optimized PEEP), conservative fluid management, and prevention of ventilator-induced lung injury (VILI). In severe cases, advanced interventions such as prone positioning, neuromuscular blockade, and venovenous extracorporeal membrane oxygenation (VV-ECMO) are utilized to improve oxygenation and survival outcomes.

Key Highlights

  • In the US, incident ARDS cases are projected to increase from 547.3K in 2025 to 586.7K by 2035, reflecting a modest growth trajectory (0.7% CAGR) linked to aging population and rising critical illness incidence.
  • Despite high incidence, treatment remains entirely supportive, with no approved disease-modifying therapies, representing a major unmet clinical need.
  • Increasing research focus on anti-inflammatory, endothelial-stabilizing, and regenerative therapies is expected to shape future treatment paradigms.

Market Overview

  • The ARDS market in Italy is projected to grow from $62M in 2025 to $122M by 2035, reflecting moderate-to-strong growth driven by critical care advancements and supportive therapy utilization.
  • Market growth is not directly correlated with incidence alone but influenced by:
  • Increased use of advanced ICU interventions (e.g., ECMO, ventilation technologies)
  • Rising healthcare expenditure in critical care settings
  • Current market value is largely derived from supportive care infrastructure (ventilation systems, ICU management), rather than pharmacological therapies.
  • Future market expansion will depend on the development and adoption of targeted therapies addressing the underlying inflammatory and vascular mechanisms of ARDS.

Insights driven by robust research, including:

  • In-depth interviews with leading KOLs and payers
  • Physician surveys
  • RWE analysis for claims and EHR datasets
  • Secondary research (e.g., peer-reviewed journal articles, third-party research databases)

Deliverables format and updates*:

  • Detailed Report (PDF)
  • Market Forecast Model (MS Excel-based automated dashboard)
  • Epidemiology (MS Excel; interactive tool)
  • Executive Insights (PowerPoint presentation)
  • Others: regular updates, customizations, consultant support
  • As per Thelansis's policy, we ensure that we include all the recent updates before releasing the report content and market model.

Salient features of Market Forecast model:

  • 10-year market forecast (2025-2035)
  • Bottom-up patient-based market forecasts validated through the top-down sales methodology
  • Covers clinically and commercially-relevant patient populations/ line of therapies
  • Annualized drug-level sales and patient share projections
  • Utilizes our proprietary Epilansis and Analog tool (e.g., drug uptake and erosion) datasets and conjoint analysis approach
  • Detailed methodology/sources & assumptions
  • Graphical and tabular outputs
  • Users can customize the model based on requirements

Key business questions answered:

  • How can drug development and lifecycle management strategies be optimized across G8 markets (US, EU5, Japan, and China)?
  • How large is the patient population in terms of incidence, prevalence, segments, and those receiving drug treatments?
  • What is the 10-year market outlook for sales and patient share?
  • Which events will have the greatest impact on the market's trajectory?
  • What insights do interviewed experts provide on current and emerging treatments?
  • Which pipeline products show the most promise, and what is their potential for launch and future positioning?
  • What are the key unmet needs and KOL expectations for target profiles?
  • What key regulatory and payer requirements must be met to secure drug approval and favorable market access?

Countries Covered

  • G8
    • United States
    • EU5
      • France
      • Germany
      • Italy
      • Spain
      • U.K.
    • Japan
    • China

Apart from the G8 Market, adding any additional country data to the dashboard will cost USD 1,750 per country

Companies Mentioned

  • Changchun Tuohua Pharmaceutical Co., Ltd.
  • Breathe Biologics, Inc.
  • Staidson (Beijing) Biopharmaceuticals Co., Ltd.
  • EnliTISA (Shanghai) Pharmaceutical Co., Ltd.
  • HTIC, Inc
  • BioAegis Therapeutics Inc.
  • Direct Biologics, LLC
  • Implicit Bioscience
  • Dompe Farmaceutici S.p.A
  • Pharmazz, Inc.
  • Aqualung Therapeutics Corp.
  • Arch Biopartners Inc.
  • Vasomune Therapeutics, Inc.
  • ImmunityBio, Inc.
  • AVM Biotechnology Inc

Table of Contents

1. Key Findings and Analyst Commentary

  • Key trends: market snapshots, SWOT analysis, commercial benefits and risks, etc.

2. Disease Context

  • Disease definition, classification, etiology and pathophysiology, drug targets, etc.

3. Epidemiology

  • Key takeaways
  • Incidence / Prevalence
  • Diagnosed and Drug-Treated populations
  • Comorbidities
  • Other relevant patient segments

4. Market Size and Forecast

  • Key takeaways
  • Market drivers and constraints
  • Drug-class specific trends
  • Country-specific trends

5. Competitive Landscape

  • Current therapies
  • Key takeaways
  • Dx and Tx journey/algorithm
  • Key current therapies - profiles and KOL insights
  • Emerging therapies
  • Key takeaways
  • Notable late-phase emerging therapies - profiles, launch expectations, KOL insights
  • Notable early-phase pipeline

6. Unmet Need and TPP Analysis

  • Top unmet needs and future attainment by emerging therapies
  • TPP analysis and KOL expectations

7. Regulatory and Reimbursement Environments (by country and payer insights)

8. Appendix (e.g., bibliography, methodology)